<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036110</url>
  </required_header>
  <id_info>
    <org_study_id>17-1809</org_study_id>
    <secondary_id>T32NR007091</secondary_id>
    <nct_id>NCT04036110</nct_id>
  </id_info>
  <brief_title>Vitamin C Supplementation Intervention</brief_title>
  <official_title>Vitamin C Supplementation Intervention for Patients With Heart Failure-A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sigma Theta Tau International Honor Society of Nursing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to test a low-cost, simple vitamin C supplementation intervention, that is,&#xD;
      comparing placebo to 500 mg/day vitamin C and 1 gram/day vitamin C daily to assess&#xD;
      feasibility and acceptability of vitamin C supplementation and effects on serum vitamin C&#xD;
      level, health-related quality of life (HRQOL), symptom burden, oxidative stress, and cardiac&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will address feasibility from the perspective of being able to: a) to detect&#xD;
      significant differences in the serum vitamin C level after supplementation (3 months) between&#xD;
      the intervention groups and the control group, b) to detect significant differences in health&#xD;
      related quality of life (HRQOL), symptom burden, oxidative stress, and cardiac function after&#xD;
      vitamin C supplementation (3 months) between the intervention groups and the control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Actual">June 16, 2020</completion_date>
  <primary_completion_date type="Actual">June 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Vitamin C Level at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Vitamin C Level at Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life Scores</measure>
    <time_frame>Baseline and up to 3 months after enrollment</time_frame>
    <description>Health related quality of life is measured using the Minnesota Living with Heart Failure questionnaire (MLHFQ). The MLHFQ is a patient-reported outcome to measure the patient's perceptions of the influence of heart failure on physical and emotional aspects of life. The questionnaire has 21 items to assess the impact of frequent physical symptoms of heart failure and the effects of heart failure on physical and emotional functions. The response scale for all 21 items on the MLHFQ is based on a 6-point (from 0 to 5). Scores are summed to a range of 0-105, in which with higher scores indicate worse health-related quality of life. Measured at Baseline and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total MSAS-HF Score</measure>
    <time_frame>Baseline and up to 3 months after enrollment</time_frame>
    <description>Symptom burden is measured using items from the Memorial Symptom Assessment Scale-Heart Failure (MSAS-HF). The MSAS-HF is an 8-item questionnaire to measure HF symptoms experienced by patients with HF. Patients will be first asked if the symptom was present during the previous 7 days. If present, three characteristics of each symptom will be rated: frequency of symptom, severity of symptom, and degree of symptom distress. Frequency is rated on a scale from 0 to 5 (1=no symptom to 5=all the time), severity rated on a scale from 0 to 5 (0=not at all to 5=extremely) and distress rated on a scale from 0 to 5 (0=not at all to 5=extremely). Burden score for each symptom can range from 0 (no burden) to 4 (greatest symptom frequency, severity, and distress). The total MAS-HF scores are summed to a range of 0-180, with higher scores indicating higher symptom burden. Measured at Baseline and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>Baseline and up to 3 months after enrollment</time_frame>
    <description>The MindWare Mobile impedance cardiograph (model number 50-2303-00) used to measure participant's cardiac function using the parameter of cardiac output. Measured at Baseline and Month 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Stress</measure>
    <time_frame>Baseline and up to 3 months after enrollment</time_frame>
    <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify 8-iso-PGF2a isoprostane in serum to reflect oxidative stress. Measured at Baseline and Month 3.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Intervention 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin C 500 mg taken daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin C 1000 mg taken daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets taken daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C 500 mg</intervention_name>
    <description>500 mg tablet taken orally with one meal daily</description>
    <arm_group_label>Intervention 1</arm_group_label>
    <other_name>L-Ascorbic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C 1000 mg</intervention_name>
    <description>1000 mg tablet taken orally with one meal daily</description>
    <arm_group_label>Intervention 2</arm_group_label>
    <other_name>L-Ascorbic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet taken orally with one meal daily</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patents recruited will have a diagnosis of chronic HF, either preserved or reduced ejection&#xD;
        fraction. The diagnosis and etiology of chronic HF will be confirmed by a HF cardiologist&#xD;
        using established criteria.&#xD;
&#xD;
        Other criteria:&#xD;
&#xD;
          -  have undergone evaluation of HF and optimization of medical therapy,&#xD;
&#xD;
          -  vitamin C supplementation &lt;500 mg/day&#xD;
&#xD;
          -  have not been referred for heart transplantation,&#xD;
&#xD;
          -  able to read and speak English,&#xD;
&#xD;
          -  &gt;1 month from any inpatient hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of renal stones or renal disease (serum creatinine &gt;1.5,&#xD;
&#xD;
          -  history of glucose-6-phosphate dehydrogenase deficiency (G6PD) and cognitive&#xD;
             impairment that precludes giving informed consent or ability to follow protocol&#xD;
             instructions&#xD;
&#xD;
          -  pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Rong Wu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNCH Meadowmont Clinic</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Carr AC, Vissers MC, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol. 2014 Oct 16;4:283. doi: 10.3389/fonc.2014.00283. eCollection 2014. Review.</citation>
    <PMID>25360419</PMID>
  </reference>
  <reference>
    <citation>Ellis GR, Anderson RA, Chirkov YY, Morris-Thurgood J, Jackson SK, Lewis MJ, Horowitz JD, Frenneaux MP. Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failure. J Cardiovasc Pharmacol. 2001 May;37(5):564-70.</citation>
    <PMID>11336107</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>December 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin C supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial will be shared, after de-identification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication from this trial.</ipd_time_frame>
    <ipd_access_criteria>Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT04036110/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study briefly suspended due to administrative reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention 1 (500 mg)</title>
          <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Intervention 2 (1000 mg)</title>
          <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
        </group>
        <group group_id="P3">
          <title>Control (Placebo)</title>
          <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Suspended</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention 1 (500 mg)</title>
          <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Intervention 2 (1000 mg)</title>
          <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
        </group>
        <group group_id="B3">
          <title>Control (Placebo)</title>
          <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="18"/>
                    <measurement group_id="B2" value="51" spread="14"/>
                    <measurement group_id="B3" value="56" spread="8"/>
                    <measurement group_id="B4" value="54" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Vitamin C Level at Baseline</title>
        <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum</description>
        <time_frame>Baseline</time_frame>
        <population>Data unreported for participants who refused to provide blood sample</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention 1 (500 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Intervention 2 (1000 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Control (Placebo)</title>
            <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Vitamin C Level at Baseline</title>
          <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum</description>
          <population>Data unreported for participants who refused to provide blood sample</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13372" spread="11555"/>
                    <measurement group_id="O2" value="16079" spread="12564"/>
                    <measurement group_id="O3" value="13111" spread="9135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Vitamin C Level at Month 3</title>
        <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum</description>
        <time_frame>Month 3</time_frame>
        <population>Data unreported for participants who refused to provide blood sample</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention 1 (500 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Intervention 2 (1000 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Control (Placebo)</title>
            <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Vitamin C Level at Month 3</title>
          <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify Vitamin C in serum</description>
          <population>Data unreported for participants who refused to provide blood sample</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21309" spread="11740"/>
                    <measurement group_id="O2" value="20574" spread="13144"/>
                    <measurement group_id="O3" value="12537" spread="7945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life Scores</title>
        <description>Health related quality of life is measured using the Minnesota Living with Heart Failure questionnaire (MLHFQ). The MLHFQ is a patient-reported outcome to measure the patient's perceptions of the influence of heart failure on physical and emotional aspects of life. The questionnaire has 21 items to assess the impact of frequent physical symptoms of heart failure and the effects of heart failure on physical and emotional functions. The response scale for all 21 items on the MLHFQ is based on a 6-point (from 0 to 5). Scores are summed to a range of 0-105, in which with higher scores indicate worse health-related quality of life. Measured at Baseline and Month 3.</description>
        <time_frame>Baseline and up to 3 months after enrollment</time_frame>
        <population>Data unreported for some participants due to study suspended and lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention 1 (500 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Intervention 2 (1000 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Control (Placebo)</title>
            <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life Scores</title>
          <description>Health related quality of life is measured using the Minnesota Living with Heart Failure questionnaire (MLHFQ). The MLHFQ is a patient-reported outcome to measure the patient's perceptions of the influence of heart failure on physical and emotional aspects of life. The questionnaire has 21 items to assess the impact of frequent physical symptoms of heart failure and the effects of heart failure on physical and emotional functions. The response scale for all 21 items on the MLHFQ is based on a 6-point (from 0 to 5). Scores are summed to a range of 0-105, in which with higher scores indicate worse health-related quality of life. Measured at Baseline and Month 3.</description>
          <population>Data unreported for some participants due to study suspended and lost to follow-up</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="32.2"/>
                    <measurement group_id="O2" value="31.4" spread="24.7"/>
                    <measurement group_id="O3" value="44.2" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" spread="23.2"/>
                    <measurement group_id="O2" value="47.4" spread="37.9"/>
                    <measurement group_id="O3" value="27.6" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total MSAS-HF Score</title>
        <description>Symptom burden is measured using items from the Memorial Symptom Assessment Scale-Heart Failure (MSAS-HF). The MSAS-HF is an 8-item questionnaire to measure HF symptoms experienced by patients with HF. Patients will be first asked if the symptom was present during the previous 7 days. If present, three characteristics of each symptom will be rated: frequency of symptom, severity of symptom, and degree of symptom distress. Frequency is rated on a scale from 0 to 5 (1=no symptom to 5=all the time), severity rated on a scale from 0 to 5 (0=not at all to 5=extremely) and distress rated on a scale from 0 to 5 (0=not at all to 5=extremely). Burden score for each symptom can range from 0 (no burden) to 4 (greatest symptom frequency, severity, and distress). The total MAS-HF scores are summed to a range of 0-180, with higher scores indicating higher symptom burden. Measured at Baseline and Month 3.</description>
        <time_frame>Baseline and up to 3 months after enrollment</time_frame>
        <population>Data unreported for some participants due to study suspended and lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention 1 (500 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Intervention 2 (1000 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Control (Placebo)</title>
            <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Total MSAS-HF Score</title>
          <description>Symptom burden is measured using items from the Memorial Symptom Assessment Scale-Heart Failure (MSAS-HF). The MSAS-HF is an 8-item questionnaire to measure HF symptoms experienced by patients with HF. Patients will be first asked if the symptom was present during the previous 7 days. If present, three characteristics of each symptom will be rated: frequency of symptom, severity of symptom, and degree of symptom distress. Frequency is rated on a scale from 0 to 5 (1=no symptom to 5=all the time), severity rated on a scale from 0 to 5 (0=not at all to 5=extremely) and distress rated on a scale from 0 to 5 (0=not at all to 5=extremely). Burden score for each symptom can range from 0 (no burden) to 4 (greatest symptom frequency, severity, and distress). The total MAS-HF scores are summed to a range of 0-180, with higher scores indicating higher symptom burden. Measured at Baseline and Month 3.</description>
          <population>Data unreported for some participants due to study suspended and lost to follow-up</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" spread="42.7"/>
                    <measurement group_id="O2" value="20.2" spread="26.6"/>
                    <measurement group_id="O3" value="31.2" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="33.3"/>
                    <measurement group_id="O2" value="24.8" spread="41.4"/>
                    <measurement group_id="O3" value="20.1" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Function</title>
        <description>The MindWare Mobile impedance cardiograph (model number 50-2303-00) used to measure participant's cardiac function using the parameter of cardiac output. Measured at Baseline and Month 3.</description>
        <time_frame>Baseline and up to 3 months after enrollment</time_frame>
        <population>Data missing due to staff learning curve using the MindWare Mobile impedance cardiograph and technical problems to detect signal from participants with pacemaker devices which caused inability to measure impedance cardiograph.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention 1 (500 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Intervention 2 (1000 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Control (Placebo)</title>
            <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Function</title>
          <description>The MindWare Mobile impedance cardiograph (model number 50-2303-00) used to measure participant's cardiac function using the parameter of cardiac output. Measured at Baseline and Month 3.</description>
          <population>Data missing due to staff learning curve using the MindWare Mobile impedance cardiograph and technical problems to detect signal from participants with pacemaker devices which caused inability to measure impedance cardiograph.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O3" value="5.6" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O3" value="14.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Stress</title>
        <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify 8-iso-PGF2a isoprostane in serum to reflect oxidative stress. Measured at Baseline and Month 3.</description>
        <time_frame>Baseline and up to 3 months after enrollment</time_frame>
        <population>Data unreported for participants who refused to provide blood sample</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention 1 (500 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Intervention 2 (1000 mg)</title>
            <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
          </group>
          <group group_id="O3">
            <title>Control (Placebo)</title>
            <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Oxidative Stress</title>
          <description>The ELISA (enzyme-linked immunosorbent assay) used to detect and quantify 8-iso-PGF2a isoprostane in serum to reflect oxidative stress. Measured at Baseline and Month 3.</description>
          <population>Data unreported for participants who refused to provide blood sample</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23144" spread="44504"/>
                    <measurement group_id="O2" value="10406" spread="27203"/>
                    <measurement group_id="O3" value="13832" spread="20676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="507" spread="262"/>
                    <measurement group_id="O2" value="2431" spread="3753"/>
                    <measurement group_id="O3" value="2580" spread="2667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline through the end of study, an approximate total of 3 months</time_frame>
      <desc>Per study protocol section 8, only pre-specified events and those events that are potentially related to participation in this research study must be collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention 1 (500 mg)</title>
          <description>Participants take vitamin C (L-Ascorbic acid) 500 mg tablet orally with one meal daily for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Intervention 2 (1000 mg)</title>
          <description>Participants take vitamin C (L-Ascorbic acid) 1000 mg tablet orally with one meal daily for 3 months</description>
        </group>
        <group group_id="E3">
          <title>Control (Placebo)</title>
          <description>Participants take vitamin C placebo (Sugar pill) tablet orally with one meal daily for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jia-Rong Wu, PhD, RN</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>859-323-4712</phone>
      <email>jiarong.wu2@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

